Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ANTISCORP-Premium is an equine-derived polyclonal antiserum developed and manufactured by Premium Serums and Vaccines Pvt Ltd for the treatment of scorpion envenomation. It consists of purified immunoglobulins obtained from the plasma of horses immunized against scorpion venom, specifically targeting the red scorpion (*Buthus tamulus*). The therapeutic mechanism involves the direct neutralization of venom toxins by these polyclonal antibodies, preventing them from binding to their physiological targets and mitigating the systemic effects of the sting. The product is typically supplied as a liquid formulation containing cresol as a preservative and is indicated for patients showing signs of systemic scorpion envenomation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ANTISCORP-Premium.